|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||23.42 - 24.25|
|52-week range||23.42 - 24.25|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) have been on a roller-coaster ride over the past few days. On May 18, Fardis notified the company she would be resigning "to pursue other opportunities." Iovance hasn't elaborated on the other opportunities Fardis will pursue, but they probably don't involve drug development.
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.